The prefilled, patient-ready-to-use system is said to support delivery of high-viscosity biologics of up to 50 centipoise.

Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable ...

Becton Dickinson (BDX) recently announced the initiation of a pharma-sponsored clinical trial featuring their BD Libertas Wearable Injector, alongside an affirmed quarterly dividend and leadership ...

Lab equipment maker Waters Corp on Monday said it will buy a bioscience and diagnostics unit spun off from medtech provider ...

Franklin Lakes, New Jersey Thursday, July 24, 2025, 14:00 Hrs [IST] ...

Becton Dickinson (BDX) announced the first pharma-sponsored combination product clinical trial using the BD Libertas Wearable Injector for ...

Milford-based biotech company Waters Corp. will merge with Becton, Dickinson and Co.’s biosciences an diagnostic solutions ...

Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 ...

Detailed price information for Becton Dickinson and Company (BDX-N) from The Globe and Mail including charting and trades.

BD has reached an agreement to merge its Biosciences & Diagnostic Solutions business with Waters Corporation in a nearly $17.5bn deal.

Waters Corporation (WAT) stock downgraded at Wells Fargo based on execution risks related to its $17.5B M&A deal with a unit of Becton Dickinson (BDX). Read more here;.